A new drug reduced recurrence or death risk by 30% in early-stage breast cancer patients, marking the first major advance in decades.

A phase 3 trial called lidERA found that giredestrant, an investigational drug for early-stage hormone receptor-positive, HER2-negative breast cancer, reduced the risk of invasive recurrence or death by 30% compared to standard endocrine therapy, with 36-month invasive disease-free survival rates of 92.4% versus 89.6%. The benefit was consistent across key patient subgroups, and the drug showed a favorable safety profile with fewer treatment discontinuations. Results, presented at the 2025 San Antonio Breast Cancer Symposium, mark the first major advance in adjuvant therapy for this common breast cancer subtype since aromatase inhibitors were introduced in 2000.